Análisis de la acción Alumis Inc. (ALMS)ALMSAlumis Inc.

Alumis Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases. Leveraging its proprietary data analytics platform and precision approach, the Company is developing a pipeline of oral tyrosine kinase 2 (TYK2) inhibitors, consisting of envudeucitinib for the treatment of systemic immune-mediated disorders, such as moderate-to-severe plaque psoriasis and systemic lupus erythematosus, and A-005 for the treatment of neuroinflammatory and neurodegenerative diseases. In addition, its pipeline also includes lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor therapy for the treatment of thyroid eye disease, as well as several preclinical programs identified through this precision approach. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alumis Inc is currently priced at $22.38, which is below several analyst price targets, including $40 from Chardan and $51 from Wells Fargo. However, the stock has a low RSI of 30.54, indicating it may be oversold. The recent insider buying activity has increased by 586.17%, suggesting confidence in the company's future. The main risk is its negative net income, which was -142,221,000 USD in Q2 2026, indicating ongoing financial challenges.